|
|
|
|
Roivant Sciences Ltd (NASDAQ: ROIV) |
|
|
|
| |
Roivant Sciences Ltd Accounts Receivables Turnover Ratio from the first quarter 2026 to the first quarter 2025
Quarterly Results, Trends, Rankings, Statistics
Roivant Sciences Ltd 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 1.39, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the first quarter 2026. Roivant Sciences Ltd 's Accounts Receivable average collection period in the Jun 30 2026 quarter, | |